Is there the role of 18F-choline PET/CT in prostate cancer patients?

Is there the role of 18F-choline PET/CT in prostate cancer patients?

Prostate cancer is the ninth-most-common cancer in the world and the most common life-threatening cancer affecting men in the western countries. More than 80% of men will develop prostate cancer by the age of 80. Physiologically, choline is a component of cell membranes. It presents a high affin...

Full description

Bibliographic Details
Main Author:	Hodolič Marina
Format:	Article
Language:	English
Published:	Institute of Oncology, Sremska Kamenica, Serbia 2012-01-01
Series:	Archive of Oncology
Subjects:	Prostatic Neoplasms Positron-Emission Tomography and Computed Tomography Choline Diagnostic Imaging Neoplasm Recurrence Local Prostate-Specific Antigen
Online Access:	http://www.doiserbia.nb.rs/img/doi/0354-7310/2012/0354-73101204084H.pdf

Similar Items

11C-Choline PET/CT and PSA kinetics
by: Castellucci Paolo, et al.
Published: (2012-01-01)

A prospective study on dual time 18F-FDG-PET/CT in high-risk prostate cancer patients
by: Mike Allan Mortensen, et al.
Published: (2018-12-01)

Dynamic 11C-Choline PET / CT for the primary diagnosis of prostate cancer
by: Shay Golan, et al.

68Ga-PSMA PET/CT versus CT and bone scan for investigation of PSA failure post radical prostatectomy
by: Yuigi Yuminaga, et al.
Published: (2021-04-01)

11C-Choline-Avid but 18F-FDG-Nonavid Prostate Cancer with Lymph Node Metastases on Positron Emission Tomography
by: Kazuhiro Kitajima, et al.
Published: (2016-11-01)

External Validation of Two Nomograms Developed for 68Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer 18F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible?
by: Henk B. Luiting, et al.
Published: (2021-06-01)

Updates of prostate cancer staging: Prostate-specific membrane antigen
by: Niranjan J Sathianathen, et al.
Published: (2016-12-01)

Value of 11C-Choline PET/CT-Based Multi-Metabolic Parameter Combination in Distinguishing Early-Stage Prostate Cancer From Benign Prostate Diseases
by: Shuoming Zhou, et al.
Published: (2021-02-01)

Performance of Ga-68 PSMA PET/CT for diagnosis and grading of local prostate cancer
by: Timothy N. Kwan, et al.
Published: (2021-06-01)

11C–Choline PET / CT in the detection of prostate cancer relapse in patients with rising PSA
by: I. P. Aslanidis, et al.
Published: (2015-09-01)

Application Progress of 68Ga-PSMA PET/CT in Recurrent Prostate Cancer
by: YANG Liping, et al.
Published: (2018-07-01)

<sup>18</sup>F–Choline PET/CT Identifies High-Grade Prostate Cancer Lesions Expressing Bone Biomarkers
by: Nicoletta Urbano, et al.
Published: (2019-10-01)

Dramatic polarization in genitourinary expert opinions regarding the clinical utility of positron emission tomography (PET) imaging in prostate cancer
by: Kiri A. Sandler, et al.

Performance and Impact of Prostate Specific Membrane Antigen-Based Diagnostics in the Management of Men with Biochemical Recurrence of Prostate Cancer and Its Role in Salvage Lymph Node Dissection
by: Marieke J. Krimphove, et al.
Published: (2020-01-01)

Impact of 68GA-PSMA PET / CT on treatment of patients with recurrent / metastatic high risk prostate cancer - a multicenter study
by: Aline B. Mattiolli, et al.

Restaging the Biochemical Recurrence of Prostate Cancer with [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT: Diagnostic Performance and Impact on Patient Disease Management
by: Aloÿse Fourquet, et al.
Published: (2021-03-01)

Nuclear medicine in prostate cancer: A new era for radiotracers
by: Vincenzo Cuccurullo, et al.
Published: (2018-01-01)

Clinical perspectives of PSMA PET/MRI for prostate cancer
by: Felipe de Galiza Barbosa, et al.
Published: (2018-09-01)

Pitfalls of FDG-PET in the prostate for the surgical oncologist
by: Ellen O'Connor, et al.
Published: (2020-11-01)

The Diagnostic Role of 18F-Choline, 18F-Fluciclovine and 18F-PSMA PET/CT in the Detection of Prostate Cancer With Biochemical Recurrence: A Meta-Analysis
by: Rang Wang, et al.
Published: (2021-06-01)

Is interim 18F-fluoride PET/CT a predictor of outcomes after radium-223 therapy?
by: Elba Etchebehere, et al.

Giant Schmorl′s Node may Cause High Uptake and Mimic a Bone Metastasis on 18 F-Choline Positron Emission Tomography/Computed Tomography
by: Gabriele Masselli, et al.
Published: (2015-01-01)

PET-CT in oncology
by: Purandare N, et al.
Published: (2010-01-01)

Prognostic Value of <sup>18</sup>F-Choline PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radium-223
by: Luca Filippi, et al.
Published: (2020-11-01)

Outcomes following negative prostate biopsy for patients with persistent disease after radiotherapy for prostate cancer
by: Jacob H. Cohen, et al.
Published: (2010-02-01)

Infrequent association between colon and prostate tumor, a clinico-radiological case
by: Alexander Sosa-Frias
Published: (2021-05-01)

Prostate-specific antigen and prostate-specific antigen kinetics in predicting 18F-sodium fluoride positron emission tomography-computed tomography positivity for first bone metastases in patients with biochemical recurrence after radical prostatectomy
by: James Yoon, et al.
Published: (2017-01-01)

PET/CT in renal and bladder cancers
by: Balenović Antonija, et al.
Published: (2012-01-01)

PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review
by: Lars J. Petersen, et al.
Published: (2020-01-01)

Uptake of prostate-specific membrane antigen-targeted18F-DCFPyL in avascular necrosis of the femoral head
by: Gonzalo Torga, et al.
Published: (2019-01-01)

SPECT/CT for tumour imaging
by: Fettich Jure, et al.
Published: (2012-01-01)

Prostate cancer nodal oligometastasis accurately assessed using prostate-specific membrane antigen positron emission tomography-computed tomography and confirmed histologically following robotic-assisted lymph node dissection
by: Dermot B O′Kane, et al.
Published: (2016-01-01)

Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
by: Sangwon Han, et al.
Published: (2021-04-01)

Potential of asphericity as a novel diagnostic parameter in the evaluation of patients with 68Ga-PSMA-HBED-CC PET-positive prostate cancer lesions
by: Sebastian Meißner, et al.
Published: (2017-10-01)

Optimization of temporal sampling for 18F-choline uptake quantification in prostate cancer assessment
by: Xavier Palard-Novello, et al.
Published: (2018-06-01)

Clinical Utility of 18F-PSMA-1007 Positron Emission Tomography/Magnetic Resonance Imaging in Prostate Cancer: A Single-Center Experience
by: Ao Liu, et al.
Published: (2021-02-01)

First case of 18F-choline uptake in acoustic schwannoma after stereotactic radiotherapy
by: Demetrio Arico, et al.
Published: (2019-01-01)

68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography for prostate cancer imaging: A narrative literature review
by: Jose M Oliveira, et al.
Published: (2017-01-01)

18F-prostate-specific membrane antigen positron emission tomography computed tomography incidental finding in a patient after COVID-19 infection
by: Siroos Mirzaei, et al.
Published: (2020-01-01)

18F-FDG PET/CT-based metabolic metrics in recurrent tumors of ovarian clear cell carcinoma and their prognostic implications
by: Shuang Ye, et al.
Published: (2019-03-01)